Plus Therapeutics (PSTV) FCF Margin (2011 - 2026)
Plus Therapeutics (PSTV) reported FCF Margin of 686.38% for Q1 2026, down 10328.0% year-over-year from N/an in Q1 2025, and down 48.82% quarter-over-quarter from 461.23% in Q4 2025.
Plus Therapeutics (PSTV) FCF Margin (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 14 years of FCF Margin data on file, last reported at 686.38% in Q1 2026.
- FCF Margin for Q1 2026 came in at 686.38%, down 10328.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 419.2% (down 18251.0% YoY), and the FY2025 annual result was 399.81%, down 21609.0% from the prior year.
- FCF Margin declined to 686.38% in Q1 2026 per PSTV's latest filing, from 461.23% in the prior quarter.
- Over five years, FCF Margin peaked at 54.75% in Q3 2023 and troughed at 5828.77% in Q3 2022.
- A 5-year average of 817.17% and a median of 271.5% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2025: FCF Margin surged 577402 bps in 2023, then sank 37469 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 1859.84% in 2022, then surged by 92 bps to 146.46% in 2023, then surged by 41 bps to 86.54% in 2024, then sank by 433 bps to 461.23% in 2025, then plunged by 49 bps to 686.38% in 2026.
- Business Quant data shows PSTV's FCF Margin at 686.38% in Q1 2026, 461.23% in Q4 2025, and 183.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | -686.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -686.38% |
| Dec 31, 2025 | -461.23% |
| Sep 30, 2025 | -183.04% |
| Jun 30, 2025 | -417.63% |
| Mar 31, 2025 | -583.10% |
| Dec 31, 2024 | -86.54% |
| Sep 30, 2024 | -253.71% |
| Jun 30, 2024 | -96.25% |
| Mar 31, 2024 | -271.50% |
| Dec 31, 2023 | -146.46% |
| Sep 30, 2023 | -54.75% |
| Jun 30, 2023 | -150.43% |
| Mar 31, 2023 | -1,178.00% |
| Dec 31, 2022 | -1,859.84% |
| Sep 30, 2022 | -5,828.77% |
| Mar 31, 2019 | -466.00% |
| Dec 31, 2018 | -175.32% |
| Sep 30, 2018 | -314.34% |
| Jun 30, 2018 | -416.06% |
| Mar 31, 2018 | -570.73% |